Related Experiment Video

Updated: Dec 25, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

Short-term single-centre experience with the HeartMate 3 left ventricular assist device for advanced heart failure

Anna Nowacka1, Roger Hullin2, Piergiorgio Tozzi1

  • 1Department of Cardiac Surgery, University Hospital, Lausanne, Switzerland.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|April 3, 2020
PubMed

Insights

The Abbott HeartMate 3 left ventricular assist device (LVAD) shows good survival rates for advanced heart failure. While technically reliable, bleeding and infection risks require careful management.

Area of Science:

  • Cardiology
  • Medical Devices
  • Mechanical Circulatory Support

Background:

  • Advanced heart failure necessitates mechanical circulatory support.
  • Left ventricular assist devices (LVADs) are crucial for end-stage heart disease.
  • The Abbott HeartMate 3 is a leading LVAD technology.

Purpose of the Study:

  • To analyze clinical characteristics, survival, and adverse events in patients with advanced heart failure receiving the Abbott HeartMate 3 LVAD.
  • To evaluate the long-term performance and safety of the HeartMate 3 LVAD.

Main Methods:

  • Retrospective review of 42 consecutive HeartMate 3 LVAD recipients.
  • Data collection on patient demographics, pre-implant status, duration of support, and outcomes.
  • Analysis of survival rates, transplant status, and adverse events including bleeding, infection, and stroke.

Main Results:

  • Actuarial survival rates at 1 and 2 years were 88.4% and 84.4%, respectively.
  • No cases of pump thrombosis or technical malfunction were reported.
  • Significant adverse events included bleeding (31%), LVAD-specific infections (45%), and ischemic stroke (12%).

Conclusions:

  • The HeartMate 3 LVAD demonstrates satisfactory survival rates and technical reliability for long-term support.
  • The device exhibits improved hemocompatibility with no reported pump thrombosis or hemolysis.
  • Bleeding complications and infections remain significant concerns requiring ongoing management strategies.
Abstract

Keywords:
ComplicationsHeartMate 3Left ventricular assist deviceSurvival

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.8K
Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.9K

Related Concept Videos

Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
465
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
237
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
373
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
289
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
350
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
189